Literature DB >> 16978382

Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes.

Y Tsutsumi1, X Jie, K Ihara, A Nomura, S Kanemitsu, H Takada, T Hara.   

Abstract

AIMS: To investigate the contribution of regulatory T cells and co-stimulatory molecules in CD4(+) T cells to the development of Type 1 diabetes (T1D).
METHODS: Twelve patients with T1D, nine patients with systemic lupus erythematosus (SLE), and 12 age-matched healthy control subjects participated. We analysed the proportions of CD25(+)CD4(+) T cells and natural killer T cells (NKT cells), and the expression levels of Foxp3, CTLA-4, CD28, ICOS, PD-1 and BTLA in peripheral blood mononuclear cells and purified CD4(+) T cells.
RESULTS: There were no significant differences in the proportions of CD25(+) CD4(+) T cells or NKT cells among the three groups. PD-1 expression levels of peripheral CD4(+) T cells from T1D patients were significantly lower than those from healthy control subjects (P = 0.00066). In contrast, PD-1 expression levels were similar in SLE patients and healthy control subjects. The expression levels of Foxp3, CTLA-4, CD28, ICOS and BTLA were similar in the three groups.
CONCLUSIONS: Decreased expression of the PD-1 gene in CD4(+) T cells may contribute to the development and/or maintenance of autoimmune T1D. As the population studied was small and heterogeneous, further studies are required to confirm the findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978382     DOI: 10.1111/j.1464-5491.2006.01951.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  19 in total

1.  PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children.

Authors:  Ronghua Ni; Kenji Ihara; Kenichi Miyako; Ryuichi Kuromaru; Mika Inuo; Hitoshi Kohno; Toshiro Hara
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

Review 2.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

Review 3.  Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Authors:  Lukas T Jeker; Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 4.  Presumed guilty: natural killer T cell defects and human disease.

Authors:  Stuart P Berzins; Mark J Smyth; Alan G Baxter
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

Review 5.  The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Authors:  Jeff J Subleski; Qun Jiang; Jonathan M Weiss; Robert H Wiltrout
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

6.  Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.

Authors:  Ming-Fei Liu; Chia-Tse Weng; Meng-Yu Weng
Journal:  J Biomed Biotechnol       Date:  2009-09-16

7.  Natural killer T cells: drivers or passengers in preventing human disease?

Authors:  Stuart P Berzins; David S Ritchie
Journal:  Nat Rev Immunol       Date:  2014-08-08       Impact factor: 53.106

8.  Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.

Authors:  N Mozaffarian; A E Wiedeman; A M Stevens
Journal:  Rheumatology (Oxford)       Date:  2008-07-23       Impact factor: 7.580

Review 9.  iNKT and MAIT Cell Alterations in Diabetes.

Authors:  Isabelle Magalhaes; Badr Kiaf; Agnès Lehuen
Journal:  Front Immunol       Date:  2015-07-02       Impact factor: 7.561

10.  Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus.

Authors:  Valentina Perri; Benedetta Russo; Antonino Crinò; Riccardo Schiaffini; Ezio Giorda; Marco Cappa; Maria Manuela Rosado; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2015-09-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.